Sep 28, 2022 / 06:00AM GMT
Sayoko Sasaki - Eisai Co., Ltd. - VP of Corporate Communications & ESG
Good afternoon. We now start explanation meeting for Recanemab Phase III Clarity AD study top line results, which was announced at 8:30 this morning. Thank you for joining this meeting today.
I will facilitate this meeting. My name is Sasaki from Corporate Communications. This meeting has a hybrid format with participants in this room and those connected via telephone. And as a countermeasure against COVID-19, we ask the participants in this room to wear masks. Thank you for your cooperation. Those in the room here, you had the press release announced today in presentation slides distributed on the table. Please confirm that. And those who are connected via telephone, you can see the presentation slides posted on our website. And we have simultaneous interpretation of English and Japanese: channel 1 is Japanese; English, channel #2.
Let me introduce the presenter today, CEO Haruo Naito; global AD Officer, Ivan Chan; Neurology Chief Discovery Officer, Teiji Kimura are also with us to respond to the Q&A session.
Eisai Co Ltd Lecanemab Phase 3 Study Met Primary Endpoint Call Transcript
Sep 28, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers